ArielaKarenHolmerMD

PubMed

• 2 citations
  Comparative Safety of Biologic Agents in Patients With Inflammatory Bowel Disease With Active or Recent Malignancy: A Multi-Center Cohort Study.
  Ariela K Holmer, Jiyu Luo, Kirk B Russ, Sarah Park, Jeong Yun Yang, Furkan Ertem, Jeffrey Dueker, Vu Nguyen, Simon Hong, Cameron Zenger, Jordan E Axelrad, Anthony Sofi...> ;Clinical Gastroenterology and Hepatology. 2023 Jun 1
• Risk factors for incomplete telehealth appointments among patients with inflammatory bowel disease.
  Katherine L Stone, Emma Kulekofsky, David Hudesman, Samuel Kozloff, Feza Remzi, Jordan E Axelrad, Seymour Katz, Simon J Hong, Ariela Holmer, Mara A McAdams-DeMarco, Do...> ;Therapeutic Advances in Gastroenterology. 2023 Jan 1
• 17 citations
  Cancer in Inflammatory Bowel Disease.
  Adam S Faye, Ariela K Holmer, Jordan E Axelrad> ;Gastroenterology Clinics of North America. 2022 Sep 1
• 1 citations
  A Serum Biomarker Panel Can Accurately Identify Mucosal Ulcers in Patients With Crohn's Disease.
  Ariela K Holmer, Brigid S Boland, Siddharth Singh, Jennifer Neill, Helen Le, Ara Miralles, Angelina E Collins, William J Sandborn, Parambir S Dulai> ;Inflammatory Bowel Diseases. 2023 Apr 3
• 1 citations
  Expanding targeted immune modulators in ulcerative colitis.
  Ariela K. Holmer, Siddharth Singh> ;Lancet. 2021 Jun 3
• 6 citations
  Spatial Evolution of Histologic and Endoscopic Healing in the Left and Right Colon in Patients With Ulcerative Colitis.
  Sushrut Jangi, Ariela K. Holmer, Parambir S. Dulai, Brigid S. Boland, Mark A. Valasek, Vipul Jairath, Brian G. Feagan, William J. Sandborn, Siddharth Singh> ;Clinical Gastroenterology and Hepatology. 2021 Feb 5
• 42 citations
  Systematic review with meta‐analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre‐existing inflammatory bowel diseases
  Joseph Meserve, Antonio Facciorusso, Ariela K. Holmer, Vito Annese, William J. Sandborn, Siddharth Singh> ;Alimentary Pharmacology & Therapeutics. 2021 Feb 1
• 6 citations
  Biomarkers are associated with clinical and endoscopic outcomes with vedolizumab treatment in Crohn's disease.
  Ariela K. Holmer, Robert Battat, Parambir S. Dulai, Niels Vande Casteele, Nghia Nguyen, Anjali Jain, Ara Miralles, Jennifer Neill, Helen Le, Siddharth Singh, Jesus Riv...> ;Therapeutic Advances in Gastroenterology. 2020 Nov 12
• 11 citations
  Risk of Relapse in Patients With Ulcerative Colitis With Persistent Endoscopic Healing: A Durable Treatment Endpoint.
  Sushrut Jangi, Ariela K. Holmer, Parambir S. Dulai, Brigid S. Boland, Angelina Collins, Lysianne Pham, William J. Sandborn, Siddharth Singh> ;Journal of Crohn's & Colitis. 2021 Apr 6
• 2 citations
  Editorial: pancreatic cancer risk in inflammatory bowel diseases-it's all relative.
  Ariela K. Holmer, Siddharth Singh> ;Alimentary Pharmacology & Therapeutics. 2020 Aug 1
• 19 citations
  Baseline Clearance of Infliximab Is Associated With Requirement for Colectomy in Patients With Acute Severe Ulcerative Colitis.
  Robert Battat, Amy Hemperly, Stephanie Truong, Natalie Whitmire, Brigid S. Boland, Parambir S. Dulai, Ariela K. Holmer, Nghia Nguyen, Siddharth Singh, Niels Vande Cast...> ;Clinical Gastroenterology and Hepatology. 2021 Mar 1
• 8 citations
  Using Artificial Intelligence to Identify Patients With Ulcerative Colitis in Endoscopic and Histologic Remission
  Ariela K. Holmer, Parambir S. Dulai> ;Gastroenterology. 2020 Jun 1
• 54 citations
  Effect of Lifestyle Factors on Outcomes in Patients With Inflammatory Bowel Diseases.
  Jacob J. Rozich, Ariela K. Holmer, Siddharth Singh> ;The American Journal of Gastroenterology. 2020 Jun 1
• 38 citations
  Overall and comparative safety of biologic and immunosuppressive therapy in inflammatory bowel diseases.
  Ariela K. Holmer, Siddharth Singh> ;Expert Review of Clinical Immunology. 2019 Jul 25
• Join now to see all